35 / 48
CLINALK: A French nationwide cohort retrospective study
Duruisseaux M et al Oncotarget 2017
For patients receiving next-generation
ALKis, median OS from the first
crizotinib dose was not reached
Patients receiving BSC only were older,
had poorer PS, were heavily pretreated,
and more frequently exhibited PFS on
crizotinib <median
survival was significantly longer for
patients receiving next- generation ALKis
than either those receiving subsequent
drugs other than next-generation ALKis